Capricor Therapeutics, Inc. (CAPR): Price and Financial Metrics

Capricor Therapeutics, Inc. (CAPR): $6.79

0.02 (+0.30%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add CAPR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#67 of 365

in industry

CAPR Price/Volume Stats

Current price $6.79 52-week high $8.22
Prev. close $6.77 52-week low $2.68
Day low $6.60 Volume 185,000
Day high $6.94 Avg. volume 277,179
50-day MA $4.81 Dividend yield N/A
200-day MA $4.59 Market Cap 213.91M

CAPR Stock Price Chart Interactive Chart >

CAPR POWR Grades

  • CAPR scores best on the Growth dimension, with a Growth rank ahead of 68.62% of US stocks.
  • CAPR's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
  • CAPR ranks lowest in Stability; there it ranks in the 14th percentile.

CAPR Stock Summary

  • CAPRICOR THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 1.99% of US listed stocks.
  • With a price/sales ratio of 11.37, CAPRICOR THERAPEUTICS INC has a higher such ratio than 90.56% of stocks in our set.
  • As for revenue growth, note that CAPR's revenue has grown 782.77% over the past 12 months; that beats the revenue growth of 99.01% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CAPRICOR THERAPEUTICS INC are FDMT, MRSN, ANAB, VERV, and TSVT.
  • CAPR's SEC filings can be seen here. And to visit CAPRICOR THERAPEUTICS INC's official web site, go to www.capricor.com.

CAPR Valuation Summary

  • In comparison to the median Healthcare stock, CAPR's price/sales ratio is 386.36% higher, now standing at 10.7.
  • Over the past 202 months, CAPR's price/sales ratio has gone up 5.5.

Below are key valuation metrics over time for CAPR.

Stock Date P/S P/B P/E EV/EBIT
CAPR 2023-12-29 10.7 -84.2 -5.1 -4.9
CAPR 2023-12-28 10.8 -85.2 -5.2 -5.0
CAPR 2023-12-27 11.1 -87.5 -5.3 -5.1
CAPR 2023-12-26 10.5 -82.7 -5.1 -4.8
CAPR 2023-12-22 9.8 -76.6 -4.7 -4.5
CAPR 2023-12-21 9.8 -77.0 -4.7 -4.5

CAPR Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 186.85%.
  • Its year over year price growth rate is now at -18.51%.
  • Its 3 year net income to common stockholders growth rate is now at -61.61%.
CAPR's revenue has moved up $1,271,975 over the prior 15 months.

The table below shows CAPR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.591566 6.191106 -27.48914
2022-06-30 0 8.538784 -25.04984
2022-03-31 0.204082 10.56661 -22.68869
2021-12-31 0.244898 -16.80932 -20.02252
2021-09-30 0.302728 -15.02414 -18.00993
2021-06-30 0.319591 -14.66378 -17.98824

CAPR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CAPR has a Quality Grade of D, ranking ahead of 11.34% of graded US stocks.
  • CAPR's asset turnover comes in at 0.008 -- ranking 401st of 682 Pharmaceutical Products stocks.
  • DRNA, MYMD, and PCRX are the stocks whose asset turnover ratios are most correlated with CAPR.

The table below shows CAPR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.008 1 14.774
2021-03-31 0.004 1 15.634
2020-12-31 0.010 1 19.771
2020-09-30 0.019 1 -10.307
2020-06-30 0.034 1 -6.657
2020-03-31 0.095 1 -5.229

CAPR Price Target

For more insight on analysts targets of CAPR, see our CAPR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.50 Average Broker Recommendation 1.5 (Moderate Buy)

Capricor Therapeutics, Inc. (CAPR) Company Bio


Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company was founded in 2005 and is based in Beverly Hills, California.


CAPR Latest News Stream


Event/Time News Detail
Loading, please wait...

CAPR Latest Social Stream


Loading social stream, please wait...

View Full CAPR Social Stream

Latest CAPR News From Around the Web

Below are the latest news stories about CAPRICOR THERAPEUTICS INC that investors may wish to consider to help them evaluate CAPR as an investment opportunity.

Capricor Therapeutics (NASDAQ:CAPR) shareholders are up 16% this past week, but still in the red over the last five years

Over the last month the Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) has been much stronger than before, rebounding by...

Yahoo | December 13, 2023

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

--Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku-- --HOPE-3 (Cohort A) Enrollment Complete; Topline Data Expected in the Fourth Quarter of 2024; Cohort B Enrollment Initiated-- --Company Plans to Request a Meeting with FDA in the First Quarter of 2024 to Further Discuss Opportunities for Expedited Approval Pathways-- SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR),

Yahoo | December 11, 2023

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 16, 2023

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good afternoon, ladies and gentlemen and welcome to the Capricor’s Third Quarter 2023 Financial Results and Corporate Update Call. This conference call is being recorded. I would now like to turn the conference call over to our host, Mr. AJ Bergmann, Capricor’s […]

Yahoo | November 16, 2023

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Would Trigger Milestone Payment to Capricor Under Commercialization and Distribution Deal with Nippon Shinyaku- -Positive FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application Submission- -Conference Call and Webcast Today

Yahoo | November 14, 2023

Read More 'CAPR' Stories Here

CAPR Price Returns

1-mo 56.81%
3-mo 38.85%
6-mo 98.54%
1-year 57.54%
3-year 46.97%
5-year 45.61%
YTD 38.85%
2023 26.68%
2022 31.74%
2021 -14.58%
2020 167.97%
2019 -68.78%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!